3SBio acquires global rights to gout drug pegsiticase from EnzymeRx for just over $6 million

Chinese biotechnology firm 3SBio (Nasdaq: SSRX) says that is has acquired worldwide rights of pegsiticase for all indications from privately-held US company EnzymeRx for a total consideration of $6.25 million.

Pegsiticase (Uricase-PEG 20) is a pegylated recombinant uricase derived from Candida utilis, modified by the attachment of multiple 20 kilodalton molecules of polyethylene glycol (PEG), and is being developed for the treatment of refractory gout and tumor lysis syndrome. It has been shown to profoundly lower uric acid when administered as by intravenous infusion and intramuscular injection, and was safe and well-tolerated in a pair of recent phase I clinical studies sponsored by EnzymeRx.

Pegsiticase has received Orphan Drug designation from the Food and Drug Administration for refractory gout, tumor lysis syndrome and Lesch-Nyhan Syndrome. 3SBio noted that it intends to develop pegsiticase in China and will seek partnerships for development outside of the country.